Paul David Rennert

This inventor holds 33 USPTO granted patents and 13 published patent applications and 3 EPO patents, primarily in Cancer Immunotherapy. Top assignees: Biogen Idec Ma Inc., Genetics Institute, Inc., Aleta Biotherapeutics Inc.. Active years: 1999-2024.

USPTO Granted Patents = 33 (Patent Applications = 13)

% Patents Active = 66.7

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 2.8

ph-index = 15

Forward Citations = 3,365(Granted Patents)

Location History:

Millis, MA (US) (2005 - 2013)
Holliston, MA (US) (1999 - 2024)

Company Filing History:

Genetics Institute, Inc.

patents

8 out of 8

Aleta Biotherapeutics Inc.

patents

4. 8 out of 3,523

University of Michigan

patents

5. 8 out of 16,273

USA as Represented by Secretary of the Navy

patents

6. 2 out of 1,265

Dana-Farber-Cancer Institute Inc.

Regents of the University of Minnesota

patents

11. 1 out of 3,690

The United States of America, as Represented by the Secretary, Department of Health and Human Services

patents

12. 2 out of 834,411

Other

patents

where one patent can have more than one assignee

Years Active: 1999-2024

Loading Chart...

Areas of Expertise:

CD19 Variants

Cancer Treatment

Tumor Transduction

T Cell Proliferation

Immunological Disorders

KIM-1 Antibodies

Lymphotoxin-beta Receptors

TWEAK Antagonists

BCMA Administration

TH1 and TH2 Cells

HIV Treatment

CTLA-4 Specific Antibodies

33 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11891426 - CD19 variants (2024-02-06),

2. 11807691 - Compositions and methods for treatment of cancer (2023-11-07),

3. 11207339 - Targeted cancer therapy (2021-12-28),

4. 11059904 - Compositions and methods for tumor transduction (2021-07-13),

5. 10669349 - Compositions and methods for treatment of cancer (2020-06-02),

6. 10508143 - Compositions and methods for treatment of cancer (2019-12-17),

7. 10072094 - Compositions and methods for tumor transduction (2018-09-11),

8. 10066023 - Compositions and methods for tumor transduction (2018-09-04),

9. 8440189 - Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders (2013-05-14),

10. 8287874 - Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases (2012-10-16),

11. 8206705 - KIM-1 antibodies for treatment of TH2-mediated conditions (2012-06-26),

12. 7744891 - Soluble lymphotoxin-beta receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological diseases (2010-06-29),

13. 7597887 - KIM-1 antagonists and use to modulate immune system (2009-10-06),

14. 7592007 - Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA-4 specific antibodies (2009-09-22),

15. 7579001 - Antagonists of TWEAK and of TWEAK receptor and their use to treat immunological disorders (2009-08-25),

Title: Paul David Rennert: Innovator in Cancer Therapeutics

Introduction: Paul David Rennert, based in Holliston, MA, is an esteemed inventor with a significant impact in the field of cancer treatment. With a portfolio of 24 patents, he has made substantial contributions to medical therapies, particularly in the development of innovative approaches to combat cancer.

Latest Patents: Among his latest innovations, Rennert has focused on CD19 variants. His work includes methods of identifying these variants and utilizing them for cancer treatment. Furthermore, he has developed compositions and methods for treating cancer that comprise cellular and protein therapeutics, showcasing his commitment to advancing healthcare through innovation.

Career Highlights: Rennert's professional journey includes key roles at notable companies. He has contributed to advancements at Genetics Institute, Inc., and Aleta Biotherapeutics, Inc., where he has been instrumental in developing pioneering therapies aimed at tackling complex health challenges.

Collaborations: Throughout his career, Rennert has collaborated with other prominent figures in biotechnology, including Gary S. Gray and Carl H. June. These partnerships have facilitated the sharing of knowledge and expertise, driving forward innovations that are crucial for evolving cancer therapies.

Conclusion: Paul David Rennert's work as an inventor has significantly influenced the landscape of cancer treatment. His array of patents and collaborations highlights a dedicated endeavor to improve therapeutic outcomes, reflecting the vital role of inventors in advancing medical science and technology.